TY - JOUR
T1 - Eptastigmine restores the aged rat's normal cortical spectral power pattern
AU - Braida, Daniela
AU - Ottonello, Francesco
AU - Sala, Mariaelvina
PY - 2000
Y1 - 2000
N2 - We studied the ability of eptastigmine, a second-generation acetylcholinesterase inhibitor (AChEI), to reverse the age-related increase of electroencephalogram (EEG) mean cortical spectral power in slow-wave δ activity and decrease in fast-wave α and β activity. The relative basal spectral power profile evaluated for 50 min of the old (27-30 months) in comparison to young (4-6 months) awake rats was consistently different, showing a significant increase in δ (0.2-4.0 Hz) frequency and a significant decrease of a (8.2-13.0 Hz) and β (13.2-25.0) bands. When 0.5, 1, 2, 4 mg kg-1 of eptastigmine were administered orally as single increasing doses for old and young rats 2 h prior to the EEG recordings, lasting 2 h, the relative mean spectral power difference (Δ%) showed a linear log dose-related decrease in δ activity and a progressive increase in α and β activity in old rats. Compared to vehicle, in young rats, the eptastigmine dose of 0.5 mg kg-1 produced a significant decrease in δ activity and an increase in β activity. The spontaneous motor activity, evaluated through cumulative horizontal and vertical counts for 30 min in old rats was significantly decreased when compared to young rats. Single oral treatment with eptastigmine (0.5 mg kg-1 for young and 2 mg kg-1 for old rats) given 2 h before the test did not significantly change motor activity in comparison to vehicle group of the same age. These results suggest a possible strategy to alleviate the severe slowing of neocortical EEG accompanying the cognitive decline. (C) 2000 Academic Press.
AB - We studied the ability of eptastigmine, a second-generation acetylcholinesterase inhibitor (AChEI), to reverse the age-related increase of electroencephalogram (EEG) mean cortical spectral power in slow-wave δ activity and decrease in fast-wave α and β activity. The relative basal spectral power profile evaluated for 50 min of the old (27-30 months) in comparison to young (4-6 months) awake rats was consistently different, showing a significant increase in δ (0.2-4.0 Hz) frequency and a significant decrease of a (8.2-13.0 Hz) and β (13.2-25.0) bands. When 0.5, 1, 2, 4 mg kg-1 of eptastigmine were administered orally as single increasing doses for old and young rats 2 h prior to the EEG recordings, lasting 2 h, the relative mean spectral power difference (Δ%) showed a linear log dose-related decrease in δ activity and a progressive increase in α and β activity in old rats. Compared to vehicle, in young rats, the eptastigmine dose of 0.5 mg kg-1 produced a significant decrease in δ activity and an increase in β activity. The spontaneous motor activity, evaluated through cumulative horizontal and vertical counts for 30 min in old rats was significantly decreased when compared to young rats. Single oral treatment with eptastigmine (0.5 mg kg-1 for young and 2 mg kg-1 for old rats) given 2 h before the test did not significantly change motor activity in comparison to vehicle group of the same age. These results suggest a possible strategy to alleviate the severe slowing of neocortical EEG accompanying the cognitive decline. (C) 2000 Academic Press.
KW - Acetylcholinesterase inhibitor
KW - Electroencephalogram
KW - Eptastigmine
KW - Spontaneous motor activity
KW - Young vs aged rats
UR - http://www.scopus.com/inward/record.url?scp=0033736146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033736146&partnerID=8YFLogxK
U2 - 10.1006/phrs.2000.0732
DO - 10.1006/phrs.2000.0732
M3 - Article
C2 - 11023715
AN - SCOPUS:0033736146
VL - 42
SP - 495
EP - 500
JO - Pharmacological Research
JF - Pharmacological Research
SN - 1043-6618
IS - 5
ER -